Atv 80 tablet
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Enhancing the Efficacy of Atorvastatin Calcium: Insights from Recent Research
Lyophilized Dry Emulsion Tablets for Atorvastatin Calcium
Improved Dissolution and Bioavailability
Recent advancements in the formulation of atorvastatin calcium (ATV) have shown promising results in enhancing its bioavailability and therapeutic efficacy. One notable development is the creation of lyophilized dry emulsion tablets (LDET) using a freeze-drying technique. These tablets are designed to improve the in-vitro dissolution and in-vivo performance of ATV, a drug known for its poor bioavailability.
The preparation process involves creating oil-in-water emulsions of ATV with a matrix former solution (alginate or gelatin), a sugar alcohol (mannitol), and a collapse protectant (glycine). The emulsions are then freeze-dried to form tablets. Studies have demonstrated that the type of matrix former and emulsifier significantly influence the disintegration time of these tablets. In-vitro dissolution tests revealed that LDET significantly enhance the dissolution rate of ATV compared to the plain drug.
Structural and Performance Benefits
Further analysis using Differential Scanning Calorimetry (DSC) and X-ray Diffraction (XRD) confirmed that ATV in LDET exists in an amorphous form, which is beneficial for its dissolution properties. Scanning Electron Microscopy (SEM) images showed that the tablets have an intact, porous, and non-collapsible structure, which contributes to the complete loss of ATV crystallinity.
In-vivo assessments on high-fat diet-induced hyperlipidemic rats indicated that ATV-loaded LDET significantly reduced serum and tissue lipid levels compared to a market product, suggesting a more effective treatment for hyperlipidemia.
Genetic Influences on Atorvastatin Metabolism
Metabolic Phenotypes and Genetic Polymorphisms
The metabolism and pharmacokinetics of atorvastatin can vary significantly among individuals due to genetic differences. A study conducted on a Mexican population identified four distinct ATV metabolizer phenotypes: slow, intermediate, normal, and fast. This study highlighted the impact of six gene polymorphisms on ATV plasma levels, with SLCO1B1 and ABCB1 polymorphisms having the most significant effects.
These findings underscore the importance of considering genetic factors when prescribing ATV, as they can influence the drug's efficacy and safety. Understanding these genetic interactions can help tailor treatments to individual patients, potentially improving therapeutic outcomes.
Therapeutic Vaccine for Hypertension
Phase IIa Clinical Trial
In a different approach to cardiovascular health, Protherics Plc has initiated a Phase IIa clinical trial for a therapeutic vaccine targeting hypertension. This vaccine, which includes a peptide analog of angiotensin I conjugated to a carrier protein, aims to provide a more convenient alternative to daily blood pressure medications. The trial will assess the safety and tolerability of the vaccine in patients with mild-to-moderate hypertension.
Potential Benefits
The therapeutic vaccine could significantly improve patient compliance by reducing the need for daily medication. This innovation represents a potential shift in hypertension treatment, offering a more manageable and effective solution for patients.
Conclusion
Recent research highlights significant advancements in the formulation and genetic understanding of atorvastatin calcium, as well as innovative approaches to hypertension treatment. Lyophilized dry emulsion tablets offer enhanced bioavailability and therapeutic efficacy for ATV, while genetic studies provide insights into personalized medicine. Additionally, the development of a therapeutic vaccine for hypertension could revolutionize patient compliance and treatment outcomes. These developments collectively represent a promising future for cardiovascular disease management.
Sources and full results
Most relevant research papers on this topic